<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Anticoagulants: oral; Coumarins; Warfarin; Acenocoumarol; Phenindione; Thrombosis: deep-vein; Deep-vein thrombosis; Thromboembolism; Atrial fibrillation; Atrial fibrillation; Arterial occlusion; Anticoagulants: oral: reversal; Human prothrombin complex see Dried prothrombin complex; Dried prothrombin complex; Prothrombin complex, dried; Pregnancy: anticoagulants; Anticoagulant treatment booklets; Treatment cards, anticoagulant" /><meta name="IX" content="Anticoagulants: oral; Coumarins; Warfarin; Acenocoumarol; Phenindione; Thrombosis: deep-vein; Deep-vein thrombosis; Thromboembolism; Atrial fibrillation; Atrial fibrillation; Arterial occlusion; Anticoagulants: oral: reversal; Dried prothrombin complex; Prothrombin complex, dried; Pregnancy: anticoagulants; Anticoagulant treatment booklets; Treatment cards, anticoagulant" /><meta name="IXN" content="Human prothrombin complex see Dried prothrombin complex" /><title>Coumarins and phenindione: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1485-coumarins-and-phenindione.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1485-coumarins-and-phenindione.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1485-coumarins-and-phenindione.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a> &gt; <a href="PHP1438-anticoagulants-and-protamine.htm">2.8 Anticoagulants and protamine</a> &gt; <a href="PHP1484-oral-anticoagulants.htm">2.8.2 Oral anticoagulants</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1484-oral-anticoagulants.htm" title="Previous: 2.8.2 Oral anticoagulants">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1494-warfarin-sodium.htm" title="Next: WARFARIN SODIUM">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Coumarins and phenindione</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int222-warfarin.htm">Warfarin</a>).</p></div></div><p>The oral anticoagulants <strong>warfarin</strong>, <strong>acenocoumarol</strong> and <strong>phenindione</strong>, antagonise the effects of vitamin K, and take at least 48 to 72 hours for the anticoagulant effect to develop fully; warfarin is the drug of choice. If an immediate effect is required, unfractionated or low molecular weight heparin must be given concomitantly.</p><div><h2>Uses</h2><p>Indications for these oral anticoagulants include <em>deep-vein thrombosis</em>, <em>pulmonary embolism</em>,  <em>atrial fibrillation</em> in those who are at risk of embolisation (see also <a title=" Management of arrhythmias" href="PHP893-management-of-arrhythmias.htm">section 2.3.1</a>), and <em>mechanical prosthetic heart valves</em> (to prevent emboli developing on the valves).</p><p>These oral anticoagulants should not be used in cerebral artery thrombosis or peripheral artery occlusion as first-line therapy; aspirin is more appropriate for reduction of risk in transient ischaemic attacks (see  <a title="BNF:topic: Transient ischaemic attack" href="PHP1525-transient-ischaemic-attack.htm">section 2.9</a>). Unfractionated or a low molecular weight heparin (<a title="sub-section: Parenteral anticoagulants" href="PHP1441-parenteral-anticoagulants.htm">section 2.8.1</a>) is usually preferred for the prophylaxis of venous thromboembolism in patients undergoing surgery; alternatively, warfarin can be continued in selected patients currently taking long-term warfarin and who are at high risk of thromboembolism (seek expert advice).</p></div><div><h2>Dose</h2><p>The base-line prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result. </p><p>For patients who require rapid anticoagulation the usual adult induction dose of warfarin is 5–10 mg on the first day (elderly patients should receive a lower induction dose); subsequent doses depend upon the prothrombin time, reported as INR (international normalised ratio). For patients who do not require rapid anticoagulation, a lower loading dose can be used over 3–4 weeks. The daily maintenance dose of warfarin is usually 3–9 mg (taken at the <strong>same time</strong> each day).</p></div><div><h2>Target INR</h2><p>The following indications and target INRs<cite><a href="PHP1485-coumarins-and-phenindione.htm#ID0EEGKBA" class="tooltip ID0EEGKBA">(1)</a></cite> for warfarin take into account recommendations of the British Society for Haematology<cite><a href="PHP1485-coumarins-and-phenindione.htm#PHP10588" class="tooltip PHP10588">(2)</a></cite>:</p><p>INR 2.5 for:</p><ul><li><p>treatment of deep-vein thrombosis or pulmonary embolism (including those associated with antiphospholipid syndrome or for recurrence in patients no longer receiving warfarin)</p> </li><li><p>atrial fibrillation (see also <a title="BNF:sub-section: Management of arrhythmias" href="PHP893-management-of-arrhythmias.htm">section 2.3.1</a>)</p> </li><li><p>cardioversion—target INR should be achieved at least 3 weeks before cardioversion and anticoagulation should continue for at least 4 weeks after the procedure (higher target values, such as an INR of 3, can be used for up to 4 weeks before the procedure to avoid cancellations due to low INR)</p> </li><li><p>dilated cardiomyopathy</p> </li><li><p>mitral stenosis or regurgitation in patients with either atrial fibrillation, a history of systemic embolism, a left atrial thrombus, or an enlarged left atrium</p> </li><li><p>bioprosthetic heart valves in the mitral position (treat for 3 months), or in patients with a history of systemic embolism (treat for at least 3 months), or with a left atrial thrombus at surgery (treat until clot resolves), or with other risk factors (e.g. atrial fibrillation or a low ventricular ejection fraction)</p> </li><li><p>acute arterial embolism requiring embolectomy (consider long-term treatment)</p> </li><li><p>myocardial infarction (see also <a title="BNF:target-block: Long-term management" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm#PHP1568">section 2.10.1</a>);</p> </li></ul><p>INR 3.5 for:</p><ul><li><p>recurrent deep-vein thrombosis or pulmonary embolism in patients currently receiving anticoagulation and with an INR above 2;</p> </li></ul><p>Mechanical prosthetic heart valves:</p><ul><li><p>the recommended target INR depends on the type and location of the valve, and patient-related risk factors</p> </li><li><p>consider increasing the INR target or adding an antiplatelet drug, if an embolic event occurs whilst anticoagulated at the target INR.</p> </li></ul></div><div><h2>Duration</h2><p>The risks of thromboembolism recurrence and anticoagulant-related bleeding should be considered when deciding the duration of anticoagulation.</p><p>The following durations of warfarin for the treatment of deep-vein thrombosis and pulmonary embolism reflect the recommendations of the British Society for Haematology<cite><a href="PHP1485-coumarins-and-phenindione.htm#PHP10588" class="tooltip PHP10588">(2)</a></cite>:</p><ul><li><p>6 weeks for isolated calf-vein deep-vein thrombosis</p> </li><li><p>3 months for venous thromboembolism provoked by surgery or other transient risk factor (e.g. combined oral contraceptive use, pregnancy, plaster cast)</p> </li><li><p><em>at least</em> 3 months for unprovoked proximal deep-vein thrombosis or pulmonary embolism; long-term anticoagulation may be required.</p> </li></ul></div><div><h2>Monitoring</h2><p>It is essential that the INR be determined daily or on alternate days in early days of treatment, <em>then</em> at longer intervals (depending on response<cite><a href="PHP1485-coumarins-and-phenindione.htm#ID0EDAIBA" class="tooltip ID0EDAIBA">(3)</a></cite>) <em>then</em> up to every 12 weeks.</p></div><div id="PHP1488"><h2>Haemorrhage</h2><p> The main adverse effect of all oral anticoagulants is haemorrhage. Checking the INR and omitting doses when appropriate is essential; if the anticoagulant is stopped but not reversed, the INR should be measured 2–3 days later to ensure that it is falling. The cause of an elevated INR should be investigated. The following recommendations (which take into account the recommendations of the British Society for Haematology<cite><a href="PHP1485-coumarins-and-phenindione.htm#PHP10588" class="tooltip PHP10588">(2)</a></cite>) are based on the result of the INR and whether there is major or minor bleeding; the recommendations apply to patients taking warfarin:</p><ul><li><p>Major bleeding—stop warfarin; give phytomenadione (vitamin K<sub>1</sub>) 5 mg by slow intravenous injection; give dried prothrombin complex (factors II, VII, IX, and X—<a title="monograph: DRIED PROTHROMBIN COMPLEX" href="PHP1607-dried-prothrombin-complex.htm">section 2.11</a>) 25–50 units/kg (if dried prothrombin complex unavailable, fresh frozen plasma 15 mL/kg can be given but is less effective); recombinant factor VIIa is not recommended for emergency anticoagulation reversal</p> </li><li><p>INR &gt; 8.0, minor bleeding—stop warfarin; give phytomenadione (vitamin K<sub>1</sub>) 1–3 mg by slow intravenous injection; repeat dose of phytomenadione if INR still too high after 24 hours; restart warfarin when INR &lt;5.0</p> </li><li><p>INR &gt; 8.0, no bleeding—stop warfarin; give phytomenadione (vitamin K<sub>1</sub>) 1–5 mg by mouth using the intravenous preparation orally [unlicensed use]; repeat dose of phytomenadione if INR still too high after 24 hours; restart warfarin when INR &lt;5.0</p> </li><li><p>INR 5.0–8.0, minor bleeding—stop warfarin; give phytomenadione (vitamin K<sub>1</sub>) 1–3 mg by slow intravenous injection; restart warfarin when INR &lt;5.0</p> </li><li><p>INR 5.0–8.0, no bleeding—withhold 1 or 2 doses of warfarin and reduce subsequent maintenance dose</p> </li><li><p>Unexpected bleeding at therapeutic levels—always investigate possibility of underlying cause e.g. unsuspected renal or gastro-intestinal tract pathology</p> </li></ul></div><div><h2>Peri-operative anticoagulation</h2><p>Warfarin should usually be stopped 5 days before elective surgery; phytomenadione (vitamin K<sub>1</sub>) 1–5 mg by mouth (using the intravenous preparation orally [unlicensed use]) should be given the day before surgery if the INR is ≥1.5. If haemostasis is adequate, warfarin can be resumed at the normal maintenance dose on the evening of surgery or the next day.</p><p>Patients stopping warfarin prior to surgery who are considered to be at high risk of thromboembolism (e.g. those with a venous thromboembolic event within the last 3 months, atrial fibrillation with previous stroke or transient ischaemic attack, or mitral mechanical heart valve) may require interim therapy (‘bridging’) with a low molecular weight heparin (using treatment dose). The low molecular weight heparin should be stopped at least 24 hours before surgery; if the surgery carries a high risk of bleeding, the low molecular weight heparin should not be restarted until at least 48 hours after surgery.</p><p>Patients on warfarin who require emergency surgery that can be delayed for 6–12 hours can be given intravenous phytomenadione (vitamin K<sub>1</sub>) 5 mg to reverse the anticoagulant effect. If surgery cannot be delayed, dried prothrombin complex (e.g. 25 units/kg) can be given in addition to intravenous phytomenadione (vitamin K<sub>1</sub>) and the INR checked before surgery.</p></div><div id="PHP1489"><h2>Combined anticoagulant and antiplatelet therapy</h2><p>Existing antiplatelet therapy following an acute coronary syndrome or percutaneous coronary intervention should be continued for the necessary duration according to the indication being treated (see <a title="BNF:section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>). The addition of warfarin, when indicated (e.g. for venous thromboembolism or atrial fibrillation) should be considered following an assessment of the patient’s risk of bleeding and discussion with a cardiologist. The duration of treatment with dual therapy (e.g. aspirin and warfarin) or triple therapy (e.g. aspirin with clopidogrel and warfarin) should be kept to a minimum where possible. The risk of bleeding with aspirin and warfarin dual therapy is lower than with clopidogrel and warfarin. Depending on the indications being treated and the patient’s risk of thromboembolism, it may be possible to withhold antiplatelet therapy until warfarin therapy is complete, or <em>vice versa</em> (on specialist advice) in order to reduce the length of time on dual or triple therapy. </p></div><div id="PHP1490"><h2>Hepatic impairment</h2><p>Warfarin, acenocoumarol, and phenindione should be avoided in severe impairment, especially if prothrombin time is already prolonged.</p></div><div id="PHP1491"><h2>Renal impairment</h2><p>Warfarin, acenocoumarol, and phenindione should be used with caution in mild to moderate impairment and avoided in severe impairment.</p></div><div id="PHP1492"><h2>Pregnancy</h2><p> Warfarin, acenocoumarol, and phenindione are teratogenic and should not be given in the first trimester of pregnancy. Women of child-bearing age should be warned of this danger since stopping these drugs before the sixth week of gestation may largely avoid the risk of fetal abnormality. These oral anticoagulants cross the placenta with risk of congenital malformations, and placental, fetal, or neonatal haemorrhage, especially during the last few weeks of pregnancy and at delivery. Therefore, if at all possible, they should be avoided in pregnancy, especially in the first and third trimesters. Difficult decisions may have to be made, particularly in women with prosthetic heart valves, atrial fibrillation, or with a history of recurrent venous thrombosis or pulmonary embolism.</p> </div><div id="PHP1493"><h2>Breast-feeding</h2><p>With warfarin, acenocoumarol, and phenindione there is a risk of haemorrhage which is increased by vitamin-K deficiency. Warfarin is not present in milk in significant amounts, and appears safe, but phenindione should be avoided; the manufacturer of acenocoumarol recommends prophylactic vitamin K for the infant (consult product literature).</p></div><div><h2>Treatment booklets</h2><p>Anticoagulant treatment booklets should be issued to patients, and are available for purchase from:</p><ul class="cJ"><li>3M Security Print and Systems Limited</li>  <li>Gorse Street, Chadderton</li><li>Oldham</li><li>OL9 9QH</li>  <li>Tel: 0845 610 1112</li> </ul><p>GP practices can obtain supplies through their Primary Care Trust (PCT) or Agency stores. NHS Hospitals can order supplies from <a href="https://www.nhsforms.co.uk">www.nhsforms.co.uk</a> or by emailing nhsforms@mmm.com.</p><p>These booklets include advice for patients on anticoagulant treatment, an alert card to be carried by the patient at all times, and a section for recording of INR results and dosage information. Electronic copies and further advice are also available at <a href="http://www.npsa.nhs.uk/nrls/alerts-and-directives/alerts/anticoagulant">www.npsa.nhs.uk/nrls/alerts-and-directives/alerts/anticoagulant</a>.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP1494-warfarin-sodium"><a href="PHP1494-warfarin-sodium.htm" title="WARFARIN SODIUM">WARFARIN SODIUM</a></li><li id="_PHP1499-acenocoumarol"><a href="PHP1499-acenocoumarol.htm" title="ACENOCOUMAROL">ACENOCOUMAROL</a></li><li id="_PHP1501-phenindione"><a href="PHP1501-phenindione.htm" title="PHENINDIONE">PHENINDIONE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1484-oral-anticoagulants.htm">Previous: 2.8.2 Oral anticoagulants</a> | <a class="top" href="PHP1485-coumarins-and-phenindione.htm#">Top</a> | <a accesskey="]" href="PHP1494-warfarin-sodium.htm">Next: WARFARIN SODIUM</a> ►</div><ol class="cC"><li class="footnote" id="ID0EEGKBA"><p>An INR which is within 0.5 units of the target value is generally satisfactory; larger deviations require dosage adjustment. Target values (rather than ranges) are now recommended. </p></li><li class="footnote" id="PHP10588"><p>Guidelines on Oral Anticoagulation with Warfarin—fourth edition. <em>Br J Haematol</em> 2011; <strong>154</strong>: 311–324</p></li><li class="footnote" id="ID0EDAIBA"><p>Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. See also <strong>interactions</strong>, Appendix 1 (coumarins). Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect warfarin control.</p></li></ol></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>